Time-varying serum uric acid predicts new-onset atrial fibrillation in treated hypertensive patients. The LIFE Study

Time-varying serum uric acid predicts new-onset atrial fibrillation in treated hypertensive patients. The LIFE Study

Aim: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed less new-onset atrial fibrillation (AF) in hypertensive patients receiving losartan- vs. atenolol-based treatment. Because losartan reduces serum uric acid (SUA) levels, the aim of the present study was to inve...

Full description

Saved in:
Bibliographic Details
Main Authors: Eran S. Zacks (Author), Ildri M. Stokke (Author), Kristian Wachtell (Author), Darcy A. Hille (Author), Aud Høieggen (Author), Sverre E. Kjeldsen (Author), Stevo Julius (Author), Eva Gerdts (Author), Peter M. Okin (Author), Richard B. Devereux (Author)
Format: Book
Published: Open Exploration Publishing Inc., 2022-03-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items